96 related articles for article (PubMed ID: 22937028)
1. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer.
Wang T; Lv M; Shen S; Zhou S; Wang P; Chen Y; Liu B; Yu L; Hou Y
PLoS One; 2012; 7(8):e43268. PubMed ID: 22937028
[TBL] [Abstract][Full Text] [Related]
2. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.
Wang Y; Gu J; Roth JA; Hildebrandt MA; Lippman SM; Ye Y; Minna JD; Wu X
Cancer Res; 2013 Aug; 73(15):4801-9. PubMed ID: 23774211
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
Zhang X; Wang X; Wen Y; Chen S; Zhou C; Wu F
Clin Transl Med; 2024 Apr; 14(4):e1649. PubMed ID: 38629624
[TBL] [Abstract][Full Text] [Related]
4. Identification of common microRNA between COPD and non-small cell lung cancer through pathway enrichment analysis.
Fathinavid A; Ghobadi MZ; Najafi A; Masoudi-Nejad A
BMC Genom Data; 2021 Oct; 22(1):41. PubMed ID: 34635059
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.
Boeri M; Verri C; Conte D; Roz L; Modena P; Facchinetti F; Calabrò E; Croce CM; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3713-8. PubMed ID: 21300873
[TBL] [Abstract][Full Text] [Related]
6. miRNA as biomarker in lung cancer.
Lobera ES; Varela MA; Jimenez RL; Moreno RB
Mol Biol Rep; 2023 Nov; 50(11):9521-9527. PubMed ID: 37741809
[TBL] [Abstract][Full Text] [Related]
7. The potential clinical applications and prospects of microRNAs in lung cancer.
Gao Y; Gao F; Ma JL; Sun WZ; Song LP
Onco Targets Ther; 2014; 7():901-6. PubMed ID: 24940074
[TBL] [Abstract][Full Text] [Related]
8. microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review).
Xiao YF; Yong X; Fan YH; Lü MH; Yang SM; Hu CJ
Oncol Rep; 2013 Aug; 30(2):535-44. PubMed ID: 23754129
[TBL] [Abstract][Full Text] [Related]
9. Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer.
Wozniak MB; Scelo G; Muller DC; Mukeria A; Zaridze D; Brennan P
PLoS One; 2015; 10(5):e0125026. PubMed ID: 25965386
[TBL] [Abstract][Full Text] [Related]
10. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer.
Wang RJ; Zheng YH; Wang P; Zhang JZ
Int J Clin Exp Pathol; 2015; 8(1):765-71. PubMed ID: 25755772
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
13. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer.
Yu H; Jiang L; Sun C; Li Guo L; Lin M; Huang J; Zhu L
Gene; 2014 Jan; 534(1):60-5. PubMed ID: 24404590
[TBL] [Abstract][Full Text] [Related]
14. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
15. Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers.
Natesh NS; White BM; Bennett MMC; Uz M; Kalari Kandy RR; Batra SK; Mallapragada SK; Rachagani S
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959269
[TBL] [Abstract][Full Text] [Related]
16. [Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer
with Malignant Pleural Effusion].
Zeng H; Tian P; Li W
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):653-659. PubMed ID: 34256901
[TBL] [Abstract][Full Text] [Related]
17. Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.
Sorolla MA; Sorolla A; Parisi E; Salud A; Porcel JM
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199799
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization.
Fanelli GN; Naccarato AG; Scatena C
Front Oncol; 2020; 10():569. PubMed ID: 32391266
[TBL] [Abstract][Full Text] [Related]
19. Detection of
Chu M; Zhu Y; Hu J; Zhang Z; Luo M; Ma X
Biomed Res Int; 2020; 2020():6124106. PubMed ID: 32090101
[TBL] [Abstract][Full Text] [Related]
20. MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer.
Lai XN; Li J; Tang LB; Chen WT; Zhang L; Xiong LX
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
